BeiGene
Latest round
- Series A
Last raised
- Nov 2014
Total raised
- $75M
Investors
- 4
About BeiGene
Established in 2010 and based in Massachusetts, US, BeiGene Ltd. is a biotechnology company that focuses on the research and development of innovative drugs. The company was listed on the NASDAQ Stock Exchange in February 2016, on the Hongkong Stock Exchange in August 2018 and on the Shanghai Stock Exchange in December 2021. Its stock code listed on the Shanghai Stock Exchange is 688235. The company's products include BRUKINSA, Baizean, Baihuize, and etc. The Company had 48 commercialized products and clinical-stage drug candidates, including 10 commercial-stage drugs, two filed drug candidates and 36 clinical-stage drug candidates.
Who invested in BeiGene
4 investors across 1 round
See all investors in BeiGene
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Nov 1, 2014
Amount
$75M
Investors
Questions about BeiGene
Who invested in BeiGene?
BeiGene has 4 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has BeiGene raised?
BeiGene has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did BeiGene last raise money?
BeiGene's most recent round on record is a Series A, in Nov 2014.
What does BeiGene do?
Established in 2010 and based in Massachusetts, US, BeiGene Ltd.
Where is BeiGene headquartered?
BeiGene is headquartered in Cambridge, US.
Which VCs invest in companies like BeiGene?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at BeiGene's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like BeiGene? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.